CurrentCignaPolicy N/A

Oncology - Sorafenib Preferred Specialty Management Policy

Defines Cigna's preferred specialty management requirements for sorafenib products (generic sorafenib tablets and brand Nexavar) including prior authorization, documentation, and exception criteria for coverage; applies to Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyOncology - Sorafenib Preferred Specialty Management Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateJun 18, 2025

Key ActionSubmit prior authorization with documentation of trial of generic sorafenib tablets or prescriber evidence of clinically significant allergy/serious adverse reaction to inactive ingredients when requesting Nexavar.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Preferredpreferred product

Nexavarnon-preferred product

1 yearapproval duration

Requireddocumentation

Coverage Criteria for Sorafenib Products

Nexavar exception (approve if ALL met)

Non-Preferred Product Exception Criteria (Nexavar)

Approve Nexavar for 1 year when ALL the following are met: A) Patient meets the standard Oncology - Sorafenib Prior Authorization Policy criteria;

Documentation is required. Approvals are for 1 year.

Approve Nexavar for 1 year when ALL the following are met: B) Patient has tried generic sorafenib tablets [documentation required];

Documentation may include chart notes, prescription claims records, prescription receipts, and/or other information.

Approve Nexavar for 1 year when ALL the following are met: C) Patient cannot continue to use the Preferred medication due to a formulation difference in the inactive ingredient(s) (e.g., differences in dyes, fillers, preservatives) which, per the prescriber, would result in a significant allergy or serious adverse reaction [documentation required].

Policy Summary

PayerCigna

PolicyOncology - Sorafenib Preferred Specialty Management Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateJun 18, 2025

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Requests for Nexavar that do not meet the specified exception criteria will be considered not medically necessary. Specifically, approval of Nexavar requires that the patient meet the standard Oncology - Sorafenib Prior Authorization Policy criteria, have documented trial of generic sorafenib tablets, and have prescriber documentation that the patient cannot continue the preferred medication due to a formulation difference in inactive ingredients (e.g., dyes, fillers, preservatives) that would cause a significant allergy or serious adverse reaction. If these exception criteria (trial of generic sorafenib and/or prescriber documentation of clinically significant allergy/serious adverse reaction to inactive ingredients) are not met, the request is not covered.

Provider Requirements and Actions

Prior Authorization

Prior authorization required

All medications (Preferred and Non-Preferred) require meeting the standard Oncology - Sorafenib Prior Authorization Policy criteria. Approvals are provided for 1 year.

Step Therapy

Try preferred product first

The program requires the patient to try the Preferred Product (generic sorafenib tablets) before approval of the Non-Preferred Product (Nexavar). If standard prior authorization criteria are met but a Preferred Product has not been tried, approval will be authorized for the Preferred Product.

Documentation Required

Documentation required

Documentation is required both for use of generic sorafenib tablets and for exception requests for Nexavar; acceptable documentation may include chart notes, prescription claims records, prescription receipts, and/or other information.

Denial Risk

Coding-related denials

Claims submitted without covered diagnosis and/or procedure codes under the applicable coverage policy will be denied as not covered; providers must use the most appropriate codes when billing.

Reimbursement is not allowed for services billed for conditions or diagnoses not covered under this policy.
When billing, providers must use the most appropriate codes as of the submission date.

Denial Risk

Non-preferred product exception denials

Requests for Nexavar that do not meet the non‑preferred product exception criteria (including required documentation of trial of generic sorafenib and prescriber documentation of clinically significant allergy/serious adverse reaction to inactive ingredients) will be considered not medically necessary and denied.

Key Definitions

inv-11: Preferred Product — generic sorafenib tablets

Preferred Productgeneric sorafenib tablets

Indications (policy context)Used for indications governed by the sorafenib policy (differentiated thyroid carcinoma, unresectable hepatocellular carcinoma, advanced renal cell carcinoma)

Approval durationApprovals provided for 1 year

DocumentationDocumentation is required for use of generic sorafenib tablets (e.g., chart notes, prescription claims, receipts)

inv-12: Non-Preferred Product — Nexavar (brand sorafenib tablets)

Non-Preferred ProductNexavar (brand sorafenib tablets)

Exception pathwayNexavar is covered only if the Non-Preferred Product exception criteria are met per policy

Prior authorization requirementPatient must meet the standard Oncology - Sorafenib Prior Authorization Policy criteria; all medications require prior authorization

Try preferred firstThe patient must try the Preferred Product (generic sorafenib tablets) prior to approval of Nexavar unless exception criteria are met

DenialsRequests for Nexavar that do not meet the specified exception criteria are considered not medically necessary and will be denied

Background

Sorafenib is a multikinase inhibitor indicated for differentiated thyroid carcinoma (locally recurrent or metastatic, radioactive iodine–refractory), unresectable hepatocellular carcinoma, and advanced renal cell carcinoma. This policy governs product selection between the Preferred Product (generic sorafenib tablets) and the Non-Preferred Product (Nexavar) and specifies prior authorization, documentation, and exception criteria rather than clinical indications.

Under this Preferred Specialty Management program, all sorafenib medications require meeting the standard Oncology - Sorafenib Prior Authorization Policy criteria and approvals are provided for 1 year. The program directs that the Preferred Product be tried prior to approval of the Non-Preferred Product, and documentation (e.g., chart notes, prescription claims, receipts) is required to support use of the preferred product or to justify a Nexavar exception.